Ryuta Asaumi

Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method

Takashi Yoshikado, Kenta Yoshida, Naoki Kotani et al. · Clinical Pharmacology & Therapeutics · 2016 · 92 citations

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects

Ryuta Asaumi, Kota Toshimoto, Yoshifusa Tobe et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 57 citations · Full text

Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism

Yukina Fukuchi, Kota Toshimoto, Takanori Mori et al. · Journal of Pharmaceutical Sciences · 2017 · 34 citations

Nonlinear Pharmacokinetics, Pharmacokinetic Modeling, Biochemistry +7

Expanded Physiologically‐Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction

Ryuta Asaumi, Karsten Menzel, Wooin Lee et al. · CPT Pharmacometrics & Systems Pharmacology · 2019 · 34 citations · Full text

Drug Target, Pharmacotherapy, Rifampicin Accounting +17

Robust physiologically based pharmacokinetic model of rifampicin for predicting <scp>drug–drug</scp> interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney

Ryuta Asaumi, Ken‐ichi Nunoya, Yoshiyuki Yamaura et al. · CPT Pharmacometrics & Systems Pharmacology · 2022 · 22 citations · Full text

Pharmacotherapy, P‐glycoprotein Induction, Physiologically-based Pharmacokinetic Modeling +18